These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 24136729)
1. Tumor-specific cytolysis caused by an E1B55K-attenuated adenovirus in nasopharyngeal carcinoma is augmented by cisplatin. Liu RY; Peng JL; Li YQ; Huang BJ; Lin HX; Zhou L; Luo HL; Huang W Anat Rec (Hoboken); 2013 Dec; 296(12):1833-41. PubMed ID: 24136729 [TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells. Li LX; Zhang YL; Zhou L; Ke ML; Chen JM; Fu X; Ye CL; Wu JX; Liu RY; Huang W J Transl Med; 2013 Oct; 11():257. PubMed ID: 24124726 [TBL] [Abstract][Full Text] [Related]
3. Enhanced therapeutic efficacy of adenovirus-mediated interleukin-24 gene therapy combined with ionizing radiotherapy for nasopharyngeal carcinoma. Liu J; Zhang Y; Sun P; Xie Y; Xiang J; Yang J Oncol Rep; 2013 Sep; 30(3):1165-74. PubMed ID: 23783436 [TBL] [Abstract][Full Text] [Related]
4. An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells. Liu RY; Zhou L; Zhang YL; Huang BJ; Ke ML; Chen JM; Li LX; Fu X; Wu JX; Huang W Biochem Biophys Res Commun; 2013 Dec; 442(3-4):171-6. PubMed ID: 24269822 [TBL] [Abstract][Full Text] [Related]
5. [Antitumour efficacy of a novel oncolytic adenovirus Ad-TD-RFP for human nasopharyngeal carcinoma]. Cao H; Xu K; Wang PJ; Jiang GZ; Gao DL; Wang JW; Cao FY; Wang YH Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Aug; 47(8):672-6. PubMed ID: 23141400 [TBL] [Abstract][Full Text] [Related]
6. ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts. Gu WG; Huang Y; Yuan ZY; Peng RJ; Luo HT; He ZR; Wang SS Asian Pac J Cancer Prev; 2013; 14(3):1787-90. PubMed ID: 23679274 [TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated delivery of interferon-γ gene inhibits the growth of nasopharyngeal carcinoma. Liu RY; Zhu YH; Zhou L; Zhao P; Li HL; Zhu LC; Han HY; Lin HX; Kang L; Wu JX; Huang W J Transl Med; 2012 Dec; 10():256. PubMed ID: 23272637 [TBL] [Abstract][Full Text] [Related]
8. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma. Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth. He SW; Zhang Y; Chen L; Luo WJ; Li XM; Chen Y; Huang SY; He QM; Yang XJ; Li YQ; Liu N; Zhao Y; Ma J FASEB J; 2021 Oct; 35(10):e21885. PubMed ID: 34478585 [TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma. Zhang J; Jiang Y; Yu Y; Li J Eur J Pharmacol; 2022 Jan; 915():174688. PubMed ID: 34883074 [TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of autophagy inhibitors combined with cisplatin against cisplatin-resistant nasopharyngeal cancer cells. Yin W; Xu J; Mao Y Biochem Cell Biol; 2021 Jun; 99(3):322-329. PubMed ID: 34038188 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo. Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490 [TBL] [Abstract][Full Text] [Related]
13. Exosomal ERp44 derived from ER-stressed cells strengthens cisplatin resistance of nasopharyngeal carcinoma. Xia T; Tian H; Zhang K; Zhang S; Chen W; Shi S; You Y BMC Cancer; 2021 Sep; 21(1):1003. PubMed ID: 34493236 [TBL] [Abstract][Full Text] [Related]
14. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Vollmer CM; Ribas A; Butterfield LH; Dissette VB; Andrews KJ; Eilber FC; Montejo LD; Chen AY; Hu B; Glaspy JA; McBride WH; Economou JS Cancer Res; 1999 Sep; 59(17):4369-74. PubMed ID: 10485485 [TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883 [TBL] [Abstract][Full Text] [Related]
16. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma. Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199 [TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma. Lu Y; Huang H; Yang H; Chen D; Wu S; Jiang Z; Wang R Cell Cycle; 2017 Jul; 16(14):1376-1383. PubMed ID: 28696828 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580 [TBL] [Abstract][Full Text] [Related]
19. Synergistic cytotoxicity against human tumor cell lines by oncolytic adenovirus dl1520 (ONYX-015) and melphalan. Ferguson PJ; Sykelyk A; Figueredo R; Koropatnick J Tumori; 2016; 102(1):31-9. PubMed ID: 26429639 [TBL] [Abstract][Full Text] [Related]
20. Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis. Chen L; Chan LS; Lung HL; Yip TTC; Ngan RKC; Wong JWC; Lo KW; Ng WT; Lee AWM; Tsao GSW; Lung ML; Mak NK Phytomedicine; 2019 Oct; 63():153058. PubMed ID: 31394414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]